Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Gene Mutation-Related Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 15camrelizumab 11Capecitabine 11130-nm albumin-bound paclitaxel 10pembrolizumab 8eribulin 8Paclitaxel 8Cyclophosphamide 8Epirubicin 7Gemcitabine 6Cisplatin 6tislelizumab 5apatinib 5atezolizumab 4anlotinib 4Taxes 4Nivolumab 4Docetaxel 4Bevacizumab 4toripalimab 3Vinorelbine 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Doxorubicin 3Albumin-Bound Paclitaxel 3talazoparib 2spartalizumab 2olaparib 2fluzoparib 2famitinib 2Zoledronic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Triple Negative Breast Neoplasms × Medicine, Chinese Traditional × Clear all
NCT03332368 2017-11-07

Clinical Study on Triple Negative Breast Cancer With Chinese Medicine

Longhua Hospital

Unknown
620 enrolled
Breast

Recurrence, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡